

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number
WO 2004/002535 A1

(51) International Patent Classification⁷: **A61K 48/00**, 38/00, 39/395, 31/00, A61P 9/10, C12N 15/11

(74) Agent: ÖHMAN, Ann-Marie; c/o Hormos Medical Corporation, Itäinen Pitkäkatu 4 B, FIN-20520 Turku (FI).

(21) International Application Number:
PCT/FI2003/000487

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 17 June 2003 (17.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/180,967 27 June 2002 (27.06.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **HORMOS MEDICAL CORPORATION [FI/FI]**; Itäinen Pitkäkatu 4 B, FIN-20520 Turku (FI).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **KOULU, Markku [FI/FI]**; Kotikatu 4 B 7, FIN-20700 Turku (FI). **TUOHIMAA, Jukka [FI/FI]**; Hämeenkatu 8 B 25, FIN-20500 Turku (FI). **PESONEN, Ullamari [FI/FI]**; Luodikkokuja 6, FIN-20900 Turku (FI). **KALLIO, Jaana [FI/FI]**; Ritavuorenkuja 5 as. 1, FIN-20540 Turku (FI). **KARVONEN, Matti [FI/FI]**; Rakuunantie 36 a 1, FIN-20720 Turku (FI).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/002535 A1

(54) Title: USE OF AN NPY Y2 RECEPTOR ANTAGONIST FOR TREATING DISORDERS RELATED TO ANGIOGENESIS

(57) Abstract: A method of treating or preventing a disorder related to excessive formation of vascular tissue or blood vessels, including neovascular glaucoma, retinopathy, nephropathy, a cardiovascular disease or a cancerous disease. Said method comprises administering to a patient an agent affecting the neuropeptide Y (NPY) Y2 receptor. Said agent may be an NPY Y2 receptor antagonist, such as an antisense oligonucleotide complementary to any part of the Y2 receptor mRNA, an antibody against the Y2 receptor, an aptamer, a small interfering RNA molecule (siRNA), a ribozyme or a dipeptidyl peptidase IV inhibitor.

Use of an NPY Y2 receptor antagonist for treating disorders related to angiogenesis

5

FIELD OF THE INVENTION

This invention relates to methods for prevention or treatment of diseases or disorders related to excessive formation of vascular tissue or blood vessels, i.e. any 10 disease or disorder in which angiogenesis is involved. The method is based on the use of targeted inhibition (or blocking) of neuropeptide Y (NPY) Y2 receptor mediated actions. The invention also concerns novel antisense oligonucleotides and their use in said methods as well as novel antisense oligonucleotides and their use in investigating the development of said diseases or disorders in experimental animals.

15

BACKGROUND OF THE INVENTION

The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the 20 practice, are incorporated by reference.

NPY is a neurotransmitter of the sympathetic nervous system, co-stored with noradrenaline in peripheral sympathetic nerve endings and released in response to strenuous sympathetic stimulation (Lundberg, Fried, et al. 1986 (1)). When released 25 from peripheral nerve terminals to arterial periadventitia NPY causes direct endothelium-independent vasoconstriction via stimulation vascular smooth-muscle cell receptors (Edvinsson, Emson, et al. 1983 (2); Edvinsson 1985 (3); Abounader, Villemure, et al. 1995 (4)).

30 NPY is widely expressed in the central and peripheral nervous systems and has many physiological functions such as in the control of metabolism and endocrine functions and in regulation of cardiovascular homeostasis.

- In addition to release from peripheral nerve endings to arterial periadventitia, NPY and NPY mRNA are also expressed extraneuronally in the endothelium of peripheral vessels (Loesch, Maynard, et al. 1992 (5); Zukowska-Grojec,
- 5 Karwatowska-Prokopcuk, et al. 1998 (6)). The minor proportion of circulating NPY level, derived from the endothelial cells has been implicated to act as an autocrine and paracrine mediator and to stimulate its receptors Y1 and Y2 found on the endothelium (Sanabria and Silva 1994 (7); Jackerott and Larsson 1997 (8); Zukowska-Grojec, Karwatowska-Prokopcuk, et al. 1998 (6). In addition to NPY,
- 10 the endothelium can also produce NPY[3-36], a more specific Y2 agonist, from circulating native NPY by a serine protease dipeptidyl peptidase IV (Mentlein, Dahms, et al. 1993 (9)). Recent studies have demonstrated that stimulation of endothelial NPY receptors leads to vasodilatation (Kobari, Fukuuchi, et al. 1993 (10); Torffvit & Edvinsson 1997 (11)) primarily through Y2 receptor activation
- 15 (You, Edvinsson, et al. 2001 (12)). In experimental study settings NPY has shown mitogenic action on smooth muscle tissue and vascular growth promoting properties. Grant and Zukowska demonstrated that NPY is a potent angiogenic factor that has promising potential to the revascularization of ischemic tissue (Grant and Zukowska 2000 (13)). The mitogenic effect of NPY has been speculated to be
- 20 mediated via Y1 or Y2 receptors (Zukowska-Grojec, Pruszczak et al. 1993 (14); Nilsson and Edvinsson 2000 (15)) and vascular growth promotion is mediated by inducible Y1, Y2, or Y5 receptors (Zukowska-Grojec Z, Karwatowska-Prokopcuk et al. 1998 (6)).
- 25 Angiogenesis is involved in a variety of human diseases. The NPY system and Y2 receptor has been shown to play a role in the regulation of the formation of blood vessels and to be active during the development of retinopathy (Zukowska-Grojec Z, et. al. 1998 (6); Lee EW, et al. 2003(16); Ekstrand AJ, et al. 2003(17)). Thus, identification of agents blocking the NPY mediated action thorough Y2 receptor

may have potential applications in the treatment of a variety of human diseases.

It was recently reported that a rather common Leu⁷Pro polymorphism located in the signal peptide of the prepro-NPY is associated with higher prevalence of diabetic 5 retinopathy in type 2 diabetic patients (Niskanen, Voutilainen-Kaunisto et al. 2000 (18)). This study linked the NPY system with the development of diabetic retinopathy. However, it has not earlier been suggested to treat or prevent such diseases by affecting the NPY Y2 receptor.

10 SUMMARY OF THE INVENTION

According to one aspect, this invention concerns a method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent 15 affecting the NPY Y2 receptor.

According to another aspect, this invention concerns an antisense oligonucleotide having a length ranging from 7 to 40 nucleotides, wherein said antisense oligonucleotide is complementary to any sequence of the human NPY Y2 receptor 20 mRNA.

According to a third aspect, the invention concerns an antisense oligonucleotide having a length ranging from 7 to 40 nucleotides, wherein said antisense oligonucleotide is complementary to any sequence of animal NPY Y2 receptor 25 mRNA.

According to a fourth aspect, the invention concerns a method for investigating the development of a disease or disorder related to excessive formation of vascular tissue or blood vessels in an experimental animal using an antisense oligonucleotide 30 having a length ranging from 7 to 40 nucleotides, wherein said antisense oligonucleotide is complementary to any sequence of animal NPY Y2 receptor mRNA.

According to a fifth aspect, the invention concerns a pharmaceutical composition comprising a therapeutically effective amount of an antisense oligonucleotide or a mixture of antisense oligonucleotides in a pharmaceutically acceptable carrier, said
5 oligonucleotide having a length ranging from 7 to 40 nucleotides and being complementary to any sequence of the human NPY Y2 receptor mRNA.

According to a sixth aspect, the invention concerns an expression vector including a nucleotide sequence encoding an antisense oligonucleotide having a length ranging
10 from 7 to 40 nucleotides and being complementary to any sequence of the human or animal NPY Y2 receptor mRNA, in a manner which allows expression of said antisense oligonucleotide in a mammalian cell.

BRIEF DESCRIPTION OF THE DRAWINGS

15

Figure 1 shows the human neuropeptide Y2 receptor mRNA, illustrated as cDNA (SEQ ID NO:1). Three examples of antisense oligonucleotides are inserted in bold letters: AS-1 (SEQ ID NO:2), AS-2 (SEQ ID NO:3) and AS-3 (SEQ ID NO:4). Also a published PCR primer, namely 5'-CTGGCTGTCAATGTCAAC-3' (SEQ ID
20 NO:5), complementary to the human NPY Y2 receptor mRNA is inserted.

Figure 2 shows the protein coding region of the rat neuropeptide Y2 receptor mRNA, illustrated as cDNA (SEQ ID NO:6). Nucleotide number 1 represents the start codon.

25

Figure 3 shows the development of induced retinopathy in rat puppies treated by i) vehicle, ii) scramble oligonucleotide, or iii) an antisense oligonucleotide complementary to NPY Y2 receptor mRNA

30 Figures 4 a-d show the efficacy of studied antisense molecules and their combinations in the prevention of tubular structures by hTERT-HUVEC cells.

Figure 5 shows as photographs the efficacy of different single antisense molecules and their combinations in the prevention of endothelial cell tube formation by hTERT-HUVEC cells.

5 DETAILED DESCRIPTION OF THE INVENTION

Our current results conducted using living cells derived from humans demonstrate that the antisense molecules directed against human NPY Y2 receptor mRNA are effective inhibitors of angiogenesis. Thus any compound preventing the NPY Y2 receptor transmission could be a potent inhibitor of tumor angiogenesis, and could have a more general interest in every disease in which angiogenesis is involved.

The wording "disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient" shall be understood to cover any such disease or disorder which can be treated or prevented by an agent to antagonize or block or prevent or modify the action of the NPY Y2 receptor.

Examples of diseases, the treatment of which could be clinically greatly benefited from the down regulation, or blockage of Y2 receptor, or prevention of the action of naive NPY or fragments of NPY (e.g. NPY 3/36 or 13-16, which are endogenous) on Y2 receptor are non-neoplastic pathologic conditions characterized by excessive angiogenesis, such as neovascular glaucoma, any form of retinopathy, all proliferative retinopathies including proliferative diabetic retinopathy, retinopathy of prematurity, macular degeneration, maculopathy, micro- or macrovascular eye complications caused by diabetes, nephropathy, diabetic nephropathy, rubeosis iridis, hemangiomas, angiofibromas, and psoriasis. This method is also effective for treating subjects with tumors and neoplasms, including malignant tumors and neoplasms, such as blastomas, carcinomas or sarcomas, and especially highly vascular tumors and neoplasms. Some examples of tumors that can be treated with the invention include epidermoid tumors, squamous tumors, such as head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including small cell and nonsmall cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors, vascularized skin cancers, including squamous cell

carcinoma, basal cell carcinoma, and skin cancers that can be treated by suppressing the growth of neovasculature. Other cancers that can be treated by the method according to this invention include Kaposi's sarcoma, CNS neoplasms (neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases), melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, preferably glioblastoma multiforme, and leiomyosarcoma.

5 However, the diseases or disorders are not restricted to the aforementioned list. Furthermore, the wording "disease or disorder related to excessive formation of 10 vascular tissue or blood vessels in a patient" includes further prevention of diseases or disorder directly derivable from the aforementioned conditions. Thus, for example, this wording also includes the prevention of predisposition to vision loss and blindness, which are consequences of retinopathy. Also metabolic diseases and cardiovascular diseases are included.

15

The diseases or disorders to be prevented or treated according to the method of this invention are particularly retinopathies or retinal neovascularization processes in diabetes like type I or type II diabetes, other metabolic diseases or cardiovascular diseases.

20

The term "NPY Y2 receptor" shall be understood to mean a receptor encoded by NPY Y2 receptor gene and mRNA (Gehlert, Beavers et al. 1996 (19); Rose PM, Fernandes et al. 1995 (20)) or active for NPY or a peptide fragment of NPY. Such a fragment can, for example, be the peptide fragment of NPY₃₋₃₆, NPY₁₃₋₃₆ 25 (Wimalawansa 1995 (21), Grandt el al. 1996 (22)) or N-acetyl [Leu(28,31)] NPY 24-36 (Smith-White and Potter 1999 (23)) or the like.

The term "agent" shall be understood to include the compound itself (racemic form as well as isomers), and any pharmaceutically acceptable derivatives thereof, such

as salts or esters and templates. It shall be also understood to include peptide compounds and derivatives antagonising NPY Y2 receptor. It shall be also understood to include agents that direct the action of endogenous NPY Y2 receptor agonists and ligands away from NPY Y2 receptor, thus attenuating NPY Y2

- 5 receptor action. It shall be also understood to include any agent aimed at influencing any phases of NPY Y2 receptor transcription and translation processes, and any device or instrument (genetic or other) needed for this mentioned action.

- The active agent to be administered can in principle be either an NPY Y2
10 antagonist, or a combination of an antagonist in a said NPY Y2 receptor and an agonist or an antagonist in another receptor, for example in NPY Y5 receptor. The same agent can thus be an antagonist in said NPY Y2 receptor and an agonist or an antagonist in another receptor. The same agent can thus be also a partial agonist.
15 According to a preferable embodiment of this invention, the agent is an NPY receptor antagonist. Y2 receptor antagonists have been described before in the literature. As an example can be mentioned BIIE 0246 (Doods, Gaida et al 1998 (24)). The suitable agent is, however, not restricted to the aforementioned examples. Any compound acting as a Y2 receptor antagonist is useful in the method according
20 to this invention.

- It is also believed that an agent blocking or influencing/inhibiting the action of dipeptidyl peptidase IV and therefore prevention of the catabolism of NPY to NPY₃₋₃₆ and the action of NPY₃₋₃₆ and native NPY towards NPY Y2 receptor could be
25 useful. As an example can be mentioned Dipeptidyl Peptidase IV Inhibitor P32/98 (Pospisilik, Stafford et al. 2002 (25)) and dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (Rahfeld J, Schierhorn et al 1991 (26)). The suitable agent is, however, not restricted to the aforementioned examples. Alternatively, an antisense oligonucleotide, an aptamer or an antibody directed to dipeptidyl peptidase IV
30 would also be useful.

It is also believed that a combination of action on the Y1 and Y5 receptor in addition to Y2 antagonism and could be useful.

- An Y2-receptor antagonistic molecule with a property of intrinsic NPY receptor
- 5 stimulating activity on Y1- and or Y5-receptors, which by acting on NPY Y2 and/or Y1 and/or Y5-receptors prevents the development and progression of retinopathy and nephropathy, and which blocks inappropriate (excessive) vasculoproliferative actions (potential retinopathy and nephropathy and related conditions promoting effects of excess endogenous NPY) of endogenous NPY and growth hormone and
- 10 insulin like growth factor-I. Thus it is also believed that antagonising NPY Y2 action prevents the development and progression of retinopathy and nephropathy through reducing growth hormone and insulin like growth factor-I.

- Thus, according to another embodiment of this invention the Y2 receptor antagonist
- 15 is also a Y1 or/and Y5-receptor agonist or antagonist.

According to a further embodiment, a separate Y1 and/or Y5 receptor agonist or antagonist is administered in combination with the Y2 receptor agonist.

- 20 According to further embodiments, this invention also concerns any method by which the prevention or down regulation of the action of NPY Y2 receptor is possible such as the use of an antisense oligonucleotide, modified nucleotide, sequence of combination of different kinds of nucleotides or any other sequence able to antagonize the action of NPY Y2 receptor or prevent or modify the NPY Y2
- 25 receptor synthesis, modification, activity, ligand binding, metabolism or degradation. The antisense oligonucleotide can be a DNA molecule or an RNA molecule. Ribozymes cleaving the NPY Y2 receptor mRNA are also included.

- The ribozyme technology is described for example in the following publications:
- 30 Ribozyme protocols: Turner, Philip C (editor) (27); Rossi JJ. 1999 (28); and Ellington AD, Robertson MP, Bull J.1997 (29).

Also small interfering RNA molecules would be useful (30).

According to a further alternative, the agent affecting the NPY Y2 receptor can be
5 an antibody raised against said receptor or raised against an Y2-specific epitope on
the NPY peptide. NPY receptor specific antibodies are known in the art, but they
have been used only to study the distribution of the Y2-receptor and other NPY
receptors.

10 According to still another alternative, the agent affecting the NPY Y2 receptor can
be an aptamer affecting the Y2 receptor or a Y2-specific NPY-conformation. An
aptamer is an oligonucleotide affecting the protein. Many antisense oligonucleotides
have also the ability to interact with peptides. There are known NPY aptamers
affecting the Y2-specific NPY-conformation and thereby preventing the NPY from
15 binding to the Y2 receptor. Also aptamers affecting the NPY receptor are known.
For publications relating to aptamers, see references 31-33.

20 The novel antisense oligonucleotides complementary to any sequence of the human
or animal NPY Y2 receptor mRNA, which according to the broadest definition can
be of a length ranging from 7 to 40 nucleotides, have preferably a length ranging
from 15 to 25 nucleotides, most preferably about 20 nucleotides.

25 The term "complementary" means that the antisense oligonucleotide sequence can
form hydrogen bonds with the target mRNA sequence by Watson-Crick or other
base-pair interactions. The term shall be understood to cover also sequences which
are not 100 % complementary. It is believed that lower complementarity, even as
low as 50 % or more, may work. However, 100 % complementarity is preferred.

30 In Figure 1 disclosing the human NPY Y2 receptor mRNA (shown as cDNA; SEQ
ID NO:1), three preferable antisense oligonucleotides of 20-21 nt are inserted in
bold letters. Although a suitable antisense oligonucleotide could be created to any

string of 7 to 40 nucleotides in the shown mRNA comprising 4390 nucleotides, it is believed that the best target region in the mRNA is found in the beginning of the mRNA sequence, especially in the regions 1 nt to 2100 nt and 2200 nt to 2500 nt of SEQ ID NO:1, more preferably the regions 1200 nt to 2100 nt and 2200 nt to 2400 nt of SEQ ID NO:1, and most preferable the target regions defined by the specific antisense oligonucleotides shown herein. Furthermore, regions with inter se binding nucleotides (hairpins etc.) should be avoided. The publication J Tajti et al., 1999 (34) discloses a PCR primer, namely 5'-CTGGCTGTCAATGTCAAC-3' (SEQ ID NO:5), which is complementary to the human NPY Y2 receptor mRNA (shown as cDNA) as indicated in Figure 1. This sequence was not, however, disclosed as a useful antisense. A revised sequence for human NPY Y2 receptor mRNA is available in Genbank and is set forth in SEQ ID NO:42. The coding region of SEQ ID NO:1 and SEQ ID NO:42 are identical, except for a C at nucleotide 2187 of SEQ ID NO:1 and a T at corresponding nucleotide 1431 of SEQ ID NO:42. The antisense oligonucleotides disclosed herein are identical in both sequences.

Normal, unmodified antisense oligonucleotides have low stability under physiological conditions because of its degradation by enzymes present in the living cell. It is therefore highly desirable to modify the antisense oligonucleotide according to known methods so as to enhance its stability against chemical and enzymatic degradation.

Modifications of antisense oligonucleotides are extensively disclosed in prior art. Reference is made to Draper et al., US 5,612,215, which in turn lists a number of 25 patents and scientific papers concerning this technique. It is known that removal or replacement of the 2'-OH group from the ribose unit gives a better stability. Eckstein et al., WO 92/07065 and US 5,672,695 discloses the replacement of the ribose 2'-OH group with halo, amino, azido or sulphydryl groups. Sproat et al., US 5,334,711, discloses the replacement of hydrogen in the 2'-OH group by alkyl or 30 alkenyl, preferably methyl or allyl groups. Furthermore, the internucleotidic phosphodiester linkage can, for example, be modified so that one or more oxygen is replaced by sulfur, amino, alkyl or alkoxy groups. Preferable modification in the

internucleotide linkages are phosphorothioate linkages. Also the base in the nucleotides can be modified. Usman and Blatt, 2000 (35), disclose a new class of nuclease-resistant ribozymes, where the 3' end of the antisense oligonucleotide is protected by the addition of an inverted 3'-3' deoxyabasic sugar.

5

- A preferable antisense oligonucleotide is a nucleotide chain wherein one or more of the internucleotide linkages are modified, and/or wherein the oligonucleotide contains locked nucleic acid (LNA) modifications and/or wherein the oligonucleotide contains peptide nucleic acid (PNA) modifications. Margaret F Taylor, 2001 (36) discloses a great variety of modifications. According to this publication, the sugar unit can, for example also be replaced by a morpholino group. This publication further discloses that different kinds of modifications inhibits the mRNA translation in different ways. All kinds of modifications described in this article are incorporated herein by reference.

10

The PNA technology is described in Ray A and Norden, 2000 (37).

- Another preferable antisense oligonucleotide is a nucleotide chain wherein one or more of the sugar units are modified, and/or one or more of the internucleotide linkages are modified, and/or one or more of the bases are modified and/or the oligonucleotide is end-protected by an inverted deoxyabasic sugar.

- As an example of preferred embodiments can be mentioned any NPY Y2 receptor targeted sequence of antisense deoxynucleotide phosphorothioates or oligonucleotides containing locked nucleic acids or peptide nucleic acids or ribozyme. Specific preferable examples are AS-1, which is 5'-CCT CTG CAC CTA TTG GAC CC-3' (SEQ ID NO:2); AS-2, which is 5'- GTTTGTGGCCCGTATTGTTCC-3', (SEQ ID NO:3) and AS-3, which is 5'- GGCCACTGTTCTTGACC-3', (SEQ ID NO:4) or longer sequences comprising these chains of nucleotides. All antisense sequences that can recognize and bind any part of the human NPY Y2 receptor mRNA sequence, including all

occurring variations due to polymorphism in the human NPY Y2 receptor gene are also concerned.

As further examples of useful antisenses can be mentioned the sequences listed

- 5 below (SEQ ID NO:7 to SEQ ID NO:37):

5'- CTGCACCTATTGGACCCATT -3' (SEQ ID NO:7)
5'- CTCTGCACCTATTGGACCCA -3' (SEQ ID NO:8)
5'- GCCTCTGCACCTATTGGACC -3' (SEQ ID NO:9)
10 5'- CAGCCTCTGCACCTATTGGA -3' (SEQ ID NO:10)
5'- CGTATTGTTCCACCTTCATT -3' (SEQ ID NO:11)
5'- CCGTATTGTTCCACCTTCAT -3' (SEQ ID NO:12)
5'- CCCGTATTGTTCCACCTTCA -3' (SEQ ID NO:13)
5'- GCCCGTATTGTTCCACCTTC -3' (SEQ ID NO:14)
15 5'- GGCCCGTATTGTTCCACCTT -3' (SEQ ID NO:15)
5'- TTTTCCACTCCCCCATTAAG -3' (SEQ ID NO:16)
5'- ATTTTCCACTCCCCCATTA -3' (SEQ ID NO:17)
5'- CATTTCACACTCCCCCATTA -3' (SEQ ID NO:18)
5'- CCATTTCCACTCCCCCAT -3' (SEQ ID NO:19)
20 5'- CCCATTTCACCTCCCCCAT -3' (SEQ ID NO:20)
5'- CTCAACATCAGCGAATACTCCC -3' (SEQ ID NO:21)
5'- GATCTCAATCAGCGAATACT -3' (SEQ ID NO:22)
5'- GCCACAATCTCAAAGTCCGG -3' (SEQ ID NO:23)
5'- GGCCACAATCTCAAAGTCCG -3' (SEQ ID NO:24)
25 5'- GCATTTGGTGGTTTTGC -3' (SEQ ID NO:25)
5'- CCAGCATTGGTGGTTTT -3' (SEQ ID NO:26)
5'- CCACACACACCAGCATTG -3' (SEQ ID NO:27)
5'- CCACCACCAACACACCAGC -3' (SEQ ID NO:28)
5'- CGCAAACACCACCAACAC -3' (SEQ ID NO:29)
30 5'- GCCAGCTGACCGCAAACACC -3' (SEQ ID NO:30)
5'- GCCTTCTGTAGTTGCTGTT -3' (SEQ ID NO:31)
5'- GGAAAGCCTTCTGTAGTTG -3' (SEQ ID NO:32)
5'- GGCGGAGAGGAAAGCCTTTC -3' (SEQ ID NO:33)
5'- CCACTGTTCTTCTGACCTC -3' (SEQ ID NO:34)
35 5'- GCCACTGTTCTTCTGACCT -3' (SEQ ID NO:35)
5'- GGGCCACTGTTCTTCTGAC -3' (SEQ ID NO:36)
5'- GGGGCCACTGTTCTTCTGA -3' (SEQ ID NO:37)

- 40 Combinations of antisenses are also useful. Two or more of the antisense sequences SEQ ID NOs:2-4 or SEQ ID NOs:7-37 can be used, or any of these sequences can be used in combination with other antisense oligonucleotides such as human

vascular endothelial growth factor antisense (VEGF-AS, 5`-GCCTCGGCTTGTACATCTGC-3', (SEQ ID NO:41).

- The suitable agent is, however, not restricted to the aforementioned examples. Any
5 compound acting as a Y2 receptor antagonist or attenuating Y2 receptor action is useful in the method according to this invention.

- According to a further embodiment, this invention also concerns a novel antisense oligonucleotide having a length ranging from 7 to 40 nucleotides, wherein said
10 antisense oligonucleotide is complementary to any sequence of animal NPY Y2 receptor mRNA. The experimental animal is preferable a rodent such as a rat or mouse. The term "complementary" shall have the same meaning as presented above for the human sequence.
15 These antisense oligonucleotides preferably contains one or more modifications as described above.

- The invention concerns methods for investigating the development of a disease or disorder related to excessive formation of vascular tissue or blood vessels,
20 particularly any form of retinopathy, in an experimental animal using such antisense oligonucleotides complementary to animal NPY Y2 receptor mRNA.

- As an example can be mentioned any NPY Y2 receptor targeted sequence of antisense deoxynucleotide phosphorothioates or oligonucleotides containing locked
25 nucleic acids or peptide nucleic acids or ribozyme. As an example of the sequence is a sequence containing 5'-CCT CTG CAC CTA ATG GGC CC -3'(SEQ ID NO:38) corresponding to rat NPY Y2 mRNA. The suitable agent is, however, not restricted to the aforementioned example.
30 For the purpose of this invention, the NPY receptor active agent can be administered by various routes. The suitable administration forms include, for example, oral or topical formulations; parenteral injections including intraocular,

intravitreous, intravenous, intramuscular, intraperitoneal, intradermal and subcutaneous injections; and transdermal, intraurethral or rectal formulations; and inhaled and nasal formulations. Suitable oral formulations include e.g. conventional or slow-release tablets and gelatine capsules.

5

- The antisense oligonucleotides according to this invention can be administered to the individual by various methods. According to one method, the sequence may be administered as such, as complexed with a cationic lipid, packed in a liposome, incorporated in cyclodextrins, bioresorbable polymers or other suitable carrier for slow release administration, biodegradable nanoparticle or a hydrogel. For some indications, antisense oligonucleotides may be directly delivered *ex vivo* to cells or tissues with or without the aforementioned vehicles.

- In addition to direct delivery of the antisense oligonucleotide,
- 15 an antisense oligonucleotide-encoding sequence can be incorporated into an expression vector, and said vector administered to the patient. The expression vector can be a DNA sequence, such as a DNA plasmid capable of eukaryotic expression, or a viral vector. Such a viral vector is preferably based on an adenovirus, an alphavirus, an adeno-associated virus, a retrovirus or a herpes virus. Preferably, the
- 20 vector is delivered to the patient in similar manner as the antisense oligonucleotide described above. The delivery of the expression vector can be systemic, such as intravenous, intramuscular or intraperitoneal administration, or local delivery to target tissue.
- 25 The required dosage of the NPY receptor active agents will vary with the particular condition being treated, the severity of the condition, the duration of the treatment, the administration route and the specific compound being employed.

- 30 The invention will be illuminated by the following non-restrictive Experimental Section.

EXPERIMENTAL SECTION

The present study was undertaken to determine the impact of NPY Y2 receptor targeted intervention on neovascularization and development of retinopathy.

Development of retinopathy was induced to newborn rats by cyclic hyperoxia and

- 5 following relative ischemia-induced retinal neovascularization. Hyperoxemia is toxic to developing retinal vessels causing damage and hypoxia in the retina. After moving to normal air, relative hypoxia follows further promoting neovascularization of the retina.

Three groups of rat puppies were subjected for different treatments; 1) vehicle, 2)

- 10 NPY Y2 receptor targeted antisense oligonucleotide sequence, and 3) scramble oligonucleotide sequence containing the same oligonucleotides as NPY Y2 receptor targeted antisense oligonucleotide sequence. The treatments were administered intraperitoneally. The retinal vessels were investigated and retinopathic changes were compared between treatment groups.

- 15 Retinopathy was assessed after injection of fluorescent-labelled dextran to the circulation. The eyes were flat-mounted on slides and the retinal vessels were visualized and investigated by fluorescence microscopy. Statistical differences were calculated between the study groups.

20 **Retinal neovascularization protocol**

Study protocol was approved by the Joint Ethics Committee of Turku University.

Development of retinopathy was induced to newborn rats (Sprague Dawley) by cyclic hyperoxia and following relative ischemia. Hyperoxia is toxic to developing

- 25 retinal vessels causing damage and hypoxia in the retina, which induces neovascularization. After moving to normal air, relative hypoxia follows further promoting neovascularization of the retina. Hypoxia is one of the major causes of retinal neovascularization in human retinopathies also. The newborn rats were kept in a hyperoxic incubator with their mothers. Retinal neovascularization was induced 30 simultaneously for all three groups of puppies. One treatment group consisted

originally of 7 puppies, which underwent cyclic hyperoxia at the age of 3 days, continued until at the age of 14 days and remained in normal room air from the age of 14 to 17 days. The amount of oxygen inside the incubator was kept at 40% and 80% in 12 hour cycles for 10 days (days from 3 to 13).

5

Treatments

The three groups of puppies were subjected for different treatments; 1) plain vehicle, 2) NPY Y2 receptor targeted antisense oligodeoxynucleotide sequence (5'-
10 CCT CTG CAC CTA ATG GGC CC -3' (SEQ ID NO:38), containing 20 thioate modified bases) diluted in vehicle and 3) scramble oligodeoxynucleotide sequence containing the same deoxynucleotides as NPY Y2 receptor targeted antisense oligodeoxynucleotide sequence but in a random order (5'-CCA TGG TAA TCC GCC GCT CC-3' (SEQ ID NO:39), containing 20 thioate modified bases) diluted in
15 vehicle. The treatments were administered intraperitoneally. The retinal vessels were investigated and retinopathic changes were compared between treatment groups. The used NPY Y2 receptor targeted antisense deoxynucleotide sequence was designed complementary to next 20 bases from NPY Y2 gene transcription initiation codon (ATG).

20

Assessment of retinopathy and retinal neovascularization

At the age of 20 days, rats were decapitated and eyes were collected. Retinopathy and retinal neovascularization was assessed after an injection of fluorescent-labelled
25 dextran to the circulation trough heart puncture. One eye from each puppy was used for visualization of retinal vessels. The eyes were flat-mounted on slides and the retinal vessels were visualized and investigated by fluorescence microscopy. Pictures of retinas were acquired using a Leica DMR/DC100 microscope and Leica DC Wiever software.

30

Statistical methods

The amount of retinal capillaries was analyzed by counting the amount of vessels crossed by a constant length line using plot profile analysis (Image-J 2.6 program). Each retina was analyzed in 3-5 representative areas and the mean values were used for further statistical analysis. Only unfolded retinal preparations were used in order

5 to avoid artificial images of neovascularization. Five eyes from study group 1, and four eyes from study groups 2 and 3 were found unfolded and used for fluorescence microscopy and statistical analyses. Differences between study populations were calculated using Oneway anova followed by post hoc tests (Tukey HSD). P-value less than 0.05 was considered statistically significant. The results are expressed as

10 mean \pm SD and range.

Results

Retinal neovascularization and retinopathy was statistically significantly different

15 between the treatment groups ($p<0.001$, Oneway anova). In vehicle and scramble treatment groups, the fluorescein images showed clearly an irregular and disrupted retinal capillary vessel formation, which was accompanied with blurred fluorescent emitting areas (Figure 3). In Y2-antisense treatment group capillary vessel formation was regular and continuous and gives an impression of healthy retina

20 without observable pathological changes. In post hoc analyses the Y2-antisense treatment group had statistically significantly less neovascularization, when compared to both vehicle treatment group ($p<0.001$ mean difference 5.40, 95% confidence interval for the difference 2.48-8.33), and to scramble treatment group ($p<0.001$ mean difference 6.53, 95% confidence interval for the difference 3.76-

25 9.31). There was no difference in retinal neovascularization between vehicle and scramble treatment groups.

Table 1 below shows the mean values of quantitated neovascularization, representing retinopathy, in the three different study groups. The development of

30 retinopathy was evident in vehicle and scramble treated groups of puppies, whereas prevented in NPY Y2 antisense treated group.

Table 1. Characteristics and statistical analysis of the retinal preparations of different treatment groups.

Treatment group, n	Mean ± SD	Range	p-value for statistical significance
Vehicle, 4	29.99 ± 2.40	28.20 - 33.30	
Y2-antisense, 4	24.58 ± 0.84	23.75 - 25.75	*<0.001 #<0.001
Scramble, 5	31.12 ± 0.93	30.33 - 32.25	* 0.527

* Tukey HSD, compared to Vehicle. # Tukey HSD, compared to Scramble.

- 5 This study demonstrates that development of retinopathy and retinal neovascularizations can be prevented by NPY Y2-receptor targeted oligonucleotide antisense therapy, evidenced by comparison to plain vehicle and control non Y2-antisense deoxyoligonucleotide sequence. The result of this study first time emphasizes the role of NPY Y2-receptor in the treatment and prevention of
10 retinopathy and retinal neovascularization.

- Our finding of prevention of retinopathy and inappropriate vascular proliferation with NPY Y2 receptor targeted antisense therapy is novel. Only one previous study has linked NPY-system and potentially altered NPY action with diabetic retinopathy
15 (Niskanen, Voutilainen-Kaunisto et al. 2000 (18)). This finding is of therapeutic potential for prevention and treatment of diabetic retinopathy and closely related diseases due to inappropriate vascular proliferation. Therefore diabetic nephropathy is also potentially preventable and treatable with NPY Y2 receptor targeted therapy, since diabetic nephropathy is also associated with inappropriate vessel growth and
20 vascular tissue mitogenesis (Del Prete, Anglani et al. 1998 (38)). In addition, elevated immunoreactive NPY concentrations has been associated with diabetic nephropathy (Satoh, Satoh et al. 1999 (39)).

- Hypoxia induce vascular proliferation is commonly used experimental model for
25 studying the mechanisms involved in pathophysiology of retinopathy and effects of novel therapies to treat and prevent retinopathy (Smith, Shen et al. 1999 (40); Smith, Kopchick et al. 1997 (41); Ozaki, Seo et al. 2000 (42)). The used retinopathy

model has its limitations but can be considered sufficient and useful in order to elucidate receptor level mechanisms leading to and involved in the patophysiology of variety of retinopathies, since vascular damage and ischemia are essentially involved in the development of retinal neovascularization in all retinopathies.

- 5 Preventing NPY Y2 receptor action blocks retinal neovascularization and is therefore an excellent target for treatment of diabetes associated retinopathy, other proliferative retinopathies like retinopathy of prematurity and other ischemic retinopathies.
- 10 A further experiment was carried out in order to study the effect of single antisense molecules and their combinations in the prevention of endothelial cell tube formation by immortal human umbilical vein endothelial cells (hTERT-HUVECs).

Cell culture

15

- Immortal human umbilical vein endothelial cells (hTERT-HUVECs) were obtained from Geron Corporation (Menlo Park, CA, U.S.A.). hTERT-HUVECs were maintained on a gelatin-coated 100-mm dishes (Corning Costar, NY, U.S.A.) in growth medium, composed of M199 medium (Gibco, Paisley, Scotland) supplement 20 with 15% (v/v) heat-inactivated fetal bovine serum (Gibco BRL), 2 mM L-glutamine (Gibco BRL), 100 units/ml penicillin/ streptomycin (Gibco BRL), 10 units/ml heparin (Sigma) and 20 µg/ml endothelial cell growth factor (Roche Biomolecules) at 37 °C in a humified incubator with 5% CO₂ atmosphere. Experiments were performed with cells between passages 20 and 24.

25

Oligonucleotides

- The following phosphorothioate oligonucleotides were synthesized: human neuropeptide Y2-receptor mRNA antisense molecules (AS-1, namely 5'-CCTCTGCACCTATTGGACCC-3', (SEQ ID NO:2); AS-2, namely 5'-GTTTGTGGCCCGTATTGTTCC-3', (SEQ ID NO:3); AS-3, namely 5'-GGCCACTGTTCTTGACC-3', (SEQ ID NO:4); AS-1 control, sequence: 5'-

CCAGGTTATCCACGTCTCC-3' (SEQ ID NO:40), and human vascular endothelial growth factor antisense (VEGF-AS, sequence: 5'-GCCTCGGCTTGTACATCTGC-3', (SEQ ID NO:41)).

5 **Liposomes**

N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethyl ammonium methylsulfate (DOTAP) and 1,2- dioleoyl-3-phosphatidylethanolamine (DOPE) were purchased from Avanti Polar Lipids. Cationic liposomes composed of DOTAP/DOPE (1:1 by mol) were prepared as previously described (Ruponen *et al.*, 2001 (43)).

10

Transfection protocol

hTERT-HUVECs (5×10^4 cells/well) were seeded onto gelatin-coated 48-multiwell plates (Corning Costar, NY, U.S.A) and incubated overnight. For transfection, the growth medium was replaced with 400 μ l of transfection medium (M199 medium 15 supplement with 2 mM L-glutamine and 100 units/ml penicillin/ streptomycin). Oligonucleotides (final concentration 1 μ M) and DOTAP/DOPE liposomes in sterile water were first diluted in MES-HEPES buffered saline (50 mM MES, 50 mM HEPES, 75 mM NaCl, pH 7.2) and then mixed together at a charge ratio +1. The transfection mixture was allowed to stand at room temperature for 20 min and 20 the oligonucleotide/liposome complexes (100 μ l) were added dropwise to each well.

Endothelial tube formation assay

After transfection for 4 h hTERT-HUVECs were harvested after trypsin treatment, suspended in growth medium (200 μ l) and seeded in growth factor-reduced Matrigel 25 (BD Biosciences) coated 96-well plates (Corning Costar, NY, U.S.A). After incubation for 3 h cells were fixed in 4% paraformaldehyde. The formation of tubular structures in each well (7 fields/ well) was digitally captured using a Nicon Eclipse TE300 Inverted Microscope (Nikon, Tokyo, Japan) equipped with a Nicon F-601 digital camera (Nikon, Tokyo, Japan). Photographs were taken at 4x 30 magnification.

The efficacy in prevention of formation of tubular structures by hTERT-HUVECs of all 5 synthesized antisense molecules were compared against each others alone and in combination. The number of tubular structures was analyzed by using Adobe 5 Photoshop 5.5 (Adobe Systems Inc., San Jose, CA, U.S.A) and the results were expressed as means \pm SEM of three independent experiments. A set of three experiments was repeated.

Results

10

Figures 4a-d demonstrate the efficacy of studied antisense molecules in the prevention of tubular structures by hTERT-HUVECs. Figures 4a and 4b represent repeated sets of three identical assays, and figures 4c and 4d represent repeated set of other three identical assays. AS-3 antisense molecule shows the best efficacy in prevention of tubular structures formation by hTERT-HUVECs. AS-1 combined with AS-3 is the most potent alternative. The respective mean \pm SEM tube number/well values for single nucleotide assay 4a were: AS-1, 44.0 ± 5.6 ; AS-2, 70.3 ± 11.3 ; AS-3, 28 ± 7.1 ; AS-1 control, 49.3 ± 8.2 ; and control (non-treated), 60 ± 1.8 . For assay 4b: AS-1, 54.3 ± 10.1 ; AS-2, 75.0 ± 7.5 ; AS-3, 23.0 ± 6.7 ; AS-1 control, 15 57.0 ± 7.0 ; and control (non-treated), 58.0 ± 2.9 . The respective mean \pm SEM tube number/well values for combination nucleotide assays 4c was: AS-1 + AS-3, 11.3 ± 1.2 ; VEGF-AS + AS-3, 34.3 ± 4.5 ; and control (non-treated), 85.7 ± 3.4 . For assay 4d: AS-1 + AS-3, 32.3 ± 4.3 ; VEGF-AS + AS-3, 54.0 ± 8.0 ; and control (non-treated), 102.0 ± 8.9 .

20

It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the expert skilled in the field that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are 25 illustrative and should not be construed as restrictive.

30

REFERENCES

1. Lundberg JM, Terenius L, Hokfelt T et al. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. *Acta Physiol Scand* 1982;116:477-80.
- 5 2. Edvinsson L, Emson P, McCulloch J, Tatemoto K, Uddman R. Neuropeptide Y: cerebrovascular innervation and vasomotor effects in the cat. *Neurosci Lett* 1983;43:79-84.
- 10 3. Edvinsson L. Characterization of the contractile effect of neuropeptide Y in feline cerebral arteries. *Acta Physiol Scand* 1985;125:33-41.
4. Abounader R, Villemure JG, Hamel E. Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y₁ antagonist BIBP 3226. *Br J Pharmacol* 1995;116:2245-50.
- 15 5. Loesch A, Maynard KI, Burnstock G. Calcitonin gene-related pep. *Neuroscience* 1992;48:723-6.
6. Zukowska-Grojec Z, Karwatowska-Prokopcuk E, Rose W et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. *Circ Res* 1998;83:187-95.
- 20 7. Sanabria P, Silva WI. Specific ¹²⁵I neuropeptide Y binding to intact cultured bovine adrenal medulla capillary endothelial cells. *Microcirculation* 1994;1:267-73.
8. Jackerott M, Larsson LI. Immunocytochemical localization of the NPY/PYY Y₁ receptor in enteric neurons, endothelial cells, and endocrine-like cells of the rat intestinal tract. *J Histochem Cytochem* 1997;45:1643-50.
- 25 9. Mentlein R, Dahms P, Grandt D, Kruger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. *Regul Pept* 1993;49:133-44.
10. Kobari M, Fukuuchi Y, Tomita M et al. Transient cerebral vasodilatory effect of neuropeptide Y mediated by nitric oxide. *Brain Res Bull* 1993;31:443-8.
- 30 11. Torffvit O, Edvinsson L. Blockade of nitric oxide decreases the renal vasodilatory effect of neuropeptide Y in the insulin-treated diabetic rat. *Pflugers Arch* 1997;434:445-50.
12. You J, Edvinsson L, Bryan RM, Jr. Neuropeptide Y-mediated constriction and dilation in rat middle cerebral arteries. *J Cereb Blood Flow Metab* 2001;21:77-84.
- 35 13. Grant DS, Zukowska Z. Revascularization of ischemic tissues with SIKVAV and neuropeptide Y (NPY). *Adv Exp Med Biol* 2000;476:139-54.

14. Zukowska-Grojec Z, Pruszczyk P, Colton C, Yao J, Shen GH, Myers AK, Wahlestedt C. Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells. *Peptides* 1993;14(2):263-8.
- 5 15. Nilsson T, Edvinsson L. Neuropeptide Y stimulates DNA synthesis in human vascular smooth muscle cells through neuropeptide Y Y1 receptors. *Can J Physiol Pharmacol* 2000 Mar;78(3):256-9.
- 10 16. Lee EW, Grant DS, Movafagh S, Zukowska Z. Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. *Peptides*. 2003 Jan;24(1):99-106.
- 15 17. Ekstrand AJ, Cao R, Bjorndahl M, Nystrom S, Jonsson-Rylander AC, Hassani H, Hallberg B, Nordlander M, Cao Y. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. *Proc Natl Acad Sci U S A*. 2003 May 13;100(10):6033-8.
18. Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, Karvonen MK, Valve R, Pesonen U, Laakso M, Uusitupa MI, Koulu M. Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. *Exp Clin Endocrinol Diabetes* 2000;108(3):235-6.
- 20 19. Gehlert DR, Beavers LS, Johnson D, Gackenheimer SL, Schober DA, Gadski RA. Expression cloning of a human brain neuropeptide Y Y2 receptor. *Mol Pharmacol* 1996 Feb;49(2):224-8.
- 25 20. Rose PM, Fernandes P, Lynch JS, Frazier ST, Fisher SM, Kodukula K, Kienzle B, Seethala R. Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. *J Biol Chem* 1995 Sep 29;270(39):22661-4.
21. Wimalawansa SJ. Purification and biochemical characterization of neuropeptide Y2 receptor. *J Biol Chem* 1995;270(31):18523-30.
- 25 22. Grandt D, Schimiczek M, Rascher W, Feth F, Shively J, Lee TD, Davis MT, Reeve JR Jr, Michel MC. Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors. *Regul Pept* 1996;67(1):33-7.
- 30 23. Smith-White MA, Potter EK. Structure-activity analysis of N-acetyl [Leu (28,31)] NPY 24-36: a potent neuropeptide Y Y(2) receptor agonist. *Neuropeptides* 1999 Dec;33(6):526-33.
- 35 24. Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, Rudolf K. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. *Eur J Pharmacol*. 1999 Nov 19;384(2-3):R3-5.
25. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin

sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. *Diabetes* 2002 Apr;51(4):943-50.

26. Rahfeld J, Schierhorn M, Hartrodt B, Neubert K, Heins J. Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? *Biochim Biophys Acta* 1991 Jan 29;1076(2):314-6.

5 27. Ribozyme protocols: Turner, Philip C (editor). Humana Press, ISBN 0-89603-389-9, 512 pp. 1997.

28. Rossi JJ. Ribozymes, genomics and therapeutics. *Chem Biol* 6, R33-7, 1999.

10

29. Ellington AD, Robertson MP, Bull J. Ribozymes in wonderland. *Science* 276, 546-7, 1997.

15

30. McManus MT and Sharp PA. Gene silencing in mammals by small interfering RNAs. *Nat Rev Genet* 2002 Oct; 3(19):737-47.

31. Brody EN and Gold L. Aptamers as therapeutic and diagnostic agents. *J Biotechnol* 2000 Mar;74(1):5-13.

20

32. Patel DJ. Structural analysis of nucleic acid aptamers. *Curr Opin Chem Biol* 1997 Jun;1(1):32-46.

33. Stull RA and Szoka FC Jr. Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. *Pharm Res* 1995 Apr;12(4):465-83.

25

34. J Tajti et al. The human superior cervical ganglion: neuropeptides and peptide receptors. *Neuroscience Letters* 263 (1999) 121-124.

30

35. Usman, N., Blatt, L. M. (2000) Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. *J. Clin. Invest.* 106:1197-1202.

36. Margaret F Taylor. Emerging antisense technologies for gene functionalization and drug discovery. *DDT* Vol. 6, No. 15 (Suppl), 2001.

37. Ray A, Norden, B. Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future. *FASEB J* 14, 1041-1066, 2000.
- 5 38. Del Prete D, Anglani F, Ceol M, D'Angelo A, Forino M, Vianello D, Baggio B, Gambaro G. Molecular biology of diabetic glomerulosclerosis. *Nephrol Dial Transplant.* 1998;13 Suppl 8:20-5. Review.
- 10 39. Satoh C, Satoh F, Takahashi K, Murakami O, Sone M, Totsune K, Yabe T, Ohneda M, Fukuda M, Sugimura K, Ogawa S, Nagakubo H, Sato T, Mouri T. Elevated plasma immunoreactive neuropeptide Y concentrations and its increased urinary excretion in patients with advanced diabetic nephropathy. *Endocr J.* 1999 Feb;46(1):139-46.
- 15 40. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM. Essential role of growth hormone in ischemia-induced retinal neovascularization. *Science* 1997 Jun 13;276(5319):1706-9.
- 20 41. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. *Nat Med.* 1999 Dec;5(12):1390-5.
- 25 42. Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E, Okamoto N, Hofmann F, Wood JM, Campochiaro PA. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. *Am J Pathol* 2000 Feb;156(2):697-707.
43. Ruponen M, Rönkkö S, Honkakoski P, Pelkonen J, Tammi M, Urtti A (2001): Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes. *J Biol Chem* 276, 33875-33880.

CLAIMS

1. Use of an agent affecting the NPY Y2 receptor for the manufacture of a pharmaceutical preparation useful for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient.
2. The use according to claim 1 wherein said disease or disorder is any form in which angiogenesis is involved, including neovascular glaucoma, any form of retinopathy, all proliferative retinopathies including proliferative diabetic retinopathy, retinopathy of prematurity, macular degeneration, maculopathy, micro- or macrovascular eye complications caused by diabetes, nephropathy, diabetic nephropathy, rubeosis iridis, hemangiomas, angiofibromas, psoriasis, predisposition to vision loss and blindness, which are consequences of retinopathy, a metabolic disease, a cardiovascular disease or a cancerous disease.
3. The use according to claim 2 wherein the cancerous disease includes tumors and neoplasms, including malignant tumors and neoplasms, blastomas, carcinomas or sarcomas, highly vascular tumors and neoplasms, epidermoid tumors, squamous tumors, head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including small cell and nonsmall cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors, vascularized skin cancers, including squamous cell carcinoma, basal cell carcinoma, and skin cancers that can be treated by suppressing the growth of neovasculation, Kaposi's sarcoma, CNS neoplasms including neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases, melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, glioblastoma multiforme, and leiomyosarcoma.

4. The use according to claim 1 wherein said agent is an NPY Y2 receptor antagonist.
5. The use according to claim 4 wherein i) said agent also is a Y1-receptor agonist or antagonist, and/or ii) said agent also is a Y5-receptor agonist or antagonist.
6. The use according to claim 1 wherein said agent is an NPY Y2 receptor antisense oligonucleotide complementary to any sequence of the human NPY Y2 receptor mRNA, said oligonucleotide having a length ranging from 7 to 40 nucleotides.
10
7. The use according to claim 6 wherein the antisense oligonucleotide contains 15 to 25 nucleotides, wherein the antisense oligonucleotide optionally contains one or more chemical modifications of the nucleotides.
- 15 8. The use according to claim 7 wherein one or more of the internucleotide linkages are modified, and/or wherein the oligonucleotide contains locked nucleic acid (LNA) modifications and/or wherein the oligonucleotide contains peptide nucleic acid (PNA) modifications.
- 20 9. The use according to claim 7 wherein one or more of the sugar units are modified, and/or one or more of the internucleotide linkages are modified, and/or one or more of the bases are modified and/or the oligonucleotide is end-protected by an inverted deoxyabasic sugar.
- 25 10. The use according to claim 9 wherein some or all of the sugar units of the antisense oligonucleotide are 2'-deoxyribose and/or wherein the internucleotide phosphodiester linkages are replaced by phosphorothioate linkages.
11. The use according to claim 6 wherein the antisense oligonucleotide is selected
30 from a group consisting of
5'-CCTCTGCACCTATTGGACCC-3', (SEQ ID NO:2);
5'-GTTTGTGGCCCGTATTGTTCC-3', (SEQ ID NO:3);
5'-GGCCACTGTTCTTGACC-3', (SEQ ID NO:4);

- 5'- CTGCACCTATTGGACCCATT -3' (SEQ ID NO:7)
5'- CTCTGCACCTATTGGACCCA -3' (SEQ ID NO:8)
5'- GCCTCTGCACCTATTGGACC -3' (SEQ ID NO:9)
5'- CAGCCTCTGCACCTATTGGA -3' (SEQ ID NO:10)
- 5 5'- CGTATTGTTCCACCTTCATT -3' (SEQ ID NO:11)
5'- CCGTATTGTTCCACCTTCAT -3' (SEQ ID NO:12)
5'- CCCGTATTGTTCCACCTTCA -3' (SEQ ID NO:13)
5'- GCCCGTATTGTTCCACCTTC -3' (SEQ ID NO:14)
5'- GGCCCGTATTGTTCCACCTT -3' (SEQ ID NO:15)
- 10 5'- TTTCCACTCCCCCATTAAG -3' (SEQ ID NO:16)
5'- ATTTCCACTCCCCCATAA -3' (SEQ ID NO:17)
5'- CATTTCACACTCCCCCATTA -3' (SEQ ID NO:18)
5'- CCATTTCACACTCCCCATT -3' (SEQ ID NO:19)
5'- CCCATTTCACACTCCCCCAT -3' (SEQ ID NO:20)
- 15 5'- CTCAACATCAGCGAATACTCCC -3' (SEQ ID NO:21)
5'- GATCTCAATCAGCGAATACT -3' (SEQ ID NO:22)
5'- GCCACAATCTCAAAGTCCGG -3' (SEQ ID NO:23)
5'- GGCCACAATCTCAAAGTCCG -3' (SEQ ID NO:24)
5'- GCATTTGGTGGTTTTG -3' (SEQ ID NO:25)
- 20 5'- CCAGCATTGGTGGTTTT -3' (SEQ ID NO:26)
5'- CCACACACACCAGCATTTG -3' (SEQ ID NO:27)
5'- CCACCACCACACACCAGC -3' (SEQ ID NO:28)
5'- CGCAAACACCACCACACAC -3' (SEQ ID NO:29)
5'- GCCAGCTGACCGCAAACACC -3' (SEQ ID NO:30)
- 25 5'- GCCTTCTGTAGTTGCTGTT -3' (SEQ ID NO:31)
5'- GGAAAGCCTTCTGTAGTTG -3' (SEQ ID NO:32)
5'- GGCGAGAGGAAAGCCTTTC -3' (SEQ ID NO:33)
5'- CCACTGTTCTTGACCTC -3' (SEQ ID NO:34)
5'- GCCACTGTTCTTCTGACCT -3' (SEQ ID NO:35)
- 30 5'- GGGCCACTGTTCTTCTGAC -3' (SEQ ID NO:36)
5'- GGGGCCACTGTTCTTCTGA -3' (SEQ ID NO:37);

- a combination of any of two or more of the aforementioned sequences or a
combination of anyone of the aforementioned with another antisense
35 oligonucleotide such as human vascular endothelial growth factor antisense VEGF-
AS, 5'-GCCTCGGCTTGTACATCTGC-3', (SEQ ID NO:41).

12. The use according to claim 11 wherein the sugar units of the antisense
oligonucleotides are 2'-deoxyribose and wherein the internucleotide linkages are
40 phosphorothioate linkages.

13. The use according to claim 1 wherein said agent is a selected from a group
consisting of

- a peptide,
 - an antibody raised against the Y2 receptor or raised against an Y2-specific epitope on the NPY peptide,
 - an aptamer affecting the Y2 receptor or a Y2-specific NPY-conformation,
- 5 - a small interfering RNA molecule, or
- a ribozyme.
14. The use according to claim 1 wherein said agent is dipeptidylpeptidase IV inhibitor, or an antisense oligonucleotide, an aptamer or antibody directed to
10 dipeptidylpeptidase IV.
15. The use according to claim 1 wherein said agent is a combination of agents having ability to affect the action of NPY Y2 receptor.
- 15 16. An antisense oligonucleotide having a length ranging from 7 to 40 nucleotides, wherein said antisense oligonucleotide is complementary to any sequence of the human NPY Y2 receptor mRNA, provided that said antisense oligonucleotide is not 5'-CTGGCTGTCAATGTCAAC-3' (SEQ ID NO:5).
- 20 17. The antisense oligonucleotide according to claim 16, which is complementary to the human NPY Y2 receptor mRNA in the target regions 1.....2100 nt and 2200.....2500 nt.
- 25 18. The antisense oligonucleotide according to claim 16, wherein the antisense oligonucleotide contains 15 to 25 nucleotides.
19. The antisense oligonucleotide according to claim 16 wherein the antisense oligonucleotide contains one or more modifications.
- 30 20. The antisense oligonucleotide according to claim 19 wherein one or more of the internucleotide linkages are modified, and/or wherein the oligonucleotide contains

locked nucleic acid (LNA) modifications and/or wherein the oligonucleotide contains peptide nucleic acid (PNA) modifications.

21. The antisense oligonucleotide according to claim 19 wherein one or more of the
5 sugar units are modified, and/or one or more of the internucleotide linkages are
modified, and/or one or more of the bases are modified and/or the oligonucleotide is
end-protected by an inverted deoxyabasic sugar.
22. The antisense oligonucleotide according to claim 21 wherein some or all of the
10 sugar units of the antisense oligonucleotide are 2'-deoxyribose and/or wherein the
internucleotide phosphodiester linkages are replaced by phosphorothioate linkages.
23. The antisense oligonucleotide according to claim 16 wherein the antisense
oligonucleotide is selected from a group consisting of
15
- 5'-CCTCTGCACCTATTGGACCC-3', (SEQ ID NO:2);
5'-GTTTGTGGCCCGTATTGTTCC-3', (SEQ ID NO:3);
5'-GGCCACTGTTCTTCTGACC-3', (SEQ ID NO:4);
5'-CTGCACCTATTGGACCCATT -3' (SEQ ID NO:7)
20 5'-CTCTGCACCTATTGGACCCA -3' (SEQ ID NO:8)
5'-GCCTCTGCACCTATTGGACC -3' (SEQ ID NO:9)
5'-CAGCCTCTGCACCTATTGGA -3' (SEQ ID NO:10)
5'-CGTATTGTTCCACCTTCATT -3' (SEQ ID NO:11)
5'-CCGTATTGTTCCACCTTCAT -3' (SEQ ID NO:12)
25 5'-CCCGTATTGTTCCACCTTCA -3' (SEQ ID NO:13)
5'-GCCCGTATTGTTCCACCTTC -3' (SEQ ID NO:14)
5'-GGCCCGTATTGTTCCACCTT -3' (SEQ ID NO:15)
5'-TTTCCACTCCCCCATTAAG -3' (SEQ ID NO:16)
5'-ATTTCACACTCCCCCATTA -3' (SEQ ID NO:17)
30 5'-CATTTCCACCTCCCCCATTA -3' (SEQ ID NO:18)
5'-CCATTTCACACTCCCCCAT -3' (SEQ ID NO:19)
5'-CCCATTTCCACCTCCCCAT -3' (SEQ ID NO:20)
5'-CTCAATCAGCGAATACTCCC -3' (SEQ ID NO:21)
5'-GATCTCAATCAGCGAATACT -3' (SEQ ID NO:22)
35 5'-GCCACAATCTCAAAGTCCGG -3' (SEQ ID NO:23)
5'-GGCCACAATCTCAAAGTCCG -3' (SEQ ID NO:24)
5'-GCATTTCGGTGGTTTTGC -3' (SEQ ID NO:25)
5'-CCAGCATTGGTGGTTTT -3' (SEQ ID NO:26)
5'-CCACACACACCCAGCATTG -3' (SEQ ID NO:27)
40 5'-CCACCACCCACACACACCAGC -3' (SEQ ID NO:28)
5'-CGCAAACACCAACCACAC -3' (SEQ ID NO:29)

- 5'- GCCAGCTGACCGCAAACACC -3' (SEQ ID NO:30)
5'- GCCTTCTGTAGTTGCTGTT -3' (SEQ ID NO:31)
5'- GGAAAGCCTTCTGTAGTTG -3' (SEQ ID NO:32)
5'- GGCGAGAGGAAAGCCTTTC -3' (SEQ ID NO:33)
- 5 5'- CCACTGTTCTTCTGACCTC -3' (SEQ ID NO:34)
5'- GCCACTGTTCTTCTGACCT -3' (SEQ ID NO:35)
5'- GGGCCACTGTTCTTCTGAC -3' (SEQ ID NO:36) and
5'- GGGGCCACTGTTCTTCTGA -3' (SEQ ID NO:37)
- 10 24. The antisense oligonucleotide according to claim 23 wherein the sugar units of the antisense oligonucleotides are 2'-deoxyribose and wherein the internucleotide linkages are phosphorothioate linkages.
- 15 25. An antisense oligonucleotide having a length ranging from 7 to 40 nucleotides, wherein said antisense oligonucleotide is complementary to any sequence of animal NPY Y2 receptor mRNA.
- 20 26. The antisense oligonucleotide according to claim 25 which is 5'-CCT CTG CAC CTA ATG GGC CC -3' (SEQ ID NO:38 corresponding to rat NPY Y2 mRNA).
- 25 27. The antisense oligonucleotide according to claim 25 wherein said oligonucleotide contains one or more modifications.
- 30 28. The antisense oligonucleotide according to claim 26 wherein said oligonucleotide contains one or more modifications.
29. A method for investigating the development of a disease or disorder related to excessive formation of vascular tissue or blood vessels in an experimental animal using an antisense oligonucleotide according to claim 25.
30. The method according to claim 29 wherein said disease or disorder is any form of retinopathy.

31. A method for investigating the development of a disease or disorder related to excessive formation of vascular tissue or blood vessels in an experimental animal using an antisense oligonucleotide according to any of the claims 26 to 28.
- 5 32. A pharmaceutical composition comprising a therapeutically effective amount of an antisense oligonucleotide or a combination of antisense oligonucleotides according to any of the claims 16 to 24 in a pharmaceutically acceptable carrier.
- 10 33. An expression vector including a nucleotide sequence encoding the antisense oligonucleotide according to any of the claims 16 to 18, or claim 23, 25 or 26 in a manner which allows expression of said antisense oligonucleotide in a mammalian cell.
- 15 34. Method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent affecting the NPY Y2 receptor.
- 20 35. The method according to claim 34 wherein said disease or disorder is any form in which angiogenesis is involved, including neovascular glaucoma, any form of retinopathy, all proliferative retinopathies including proliferative diabetic retinopathy, retinopathy of prematurity, macular degeneration, maculopathy, micro- or macrovascular eye complications caused by diabetes, nephropathy, diabetic nephropathy, rubeosis iridis, hemangiomas, angiofibromas, psoriasis, predisposition to vision loss and blindness, which are consequences of retinopathy, a metabolic disease, a cardiovascular disease or a cancerous disease.
- 25 36. The method according to claim 35 wherein the cancerous disease includes tumors and neoplasms, including malignant tumors and neoplasms, blastomas, carcinomas or sarcomas, highly vascular tumors and neoplasms, epidermoid tumors, squamous tumors, head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including small cell and nonsmall cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors, vascularized skin cancers, including squamous cell carcinoma, basal cell carcinoma, and skin cancers that can

be treated by suppressing the growth of neovasculature, Kaposi's sarcoma, CNS neoplasms including neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases, melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, glioblastoma multiforme, and

5 leiomyosarcoma.

37. The method according to claim 34 wherein said agent is an NPY Y2 receptor antagonist.
- 10 38. The method according to claim 37 wherein i) said agent also is a Y1-receptor agonist or antagonist, and/or ii) said agent also is a Y5-receptor agonist or antagonist.
- 15 39. The method according to claim 34 wherein said agent is an NPY Y2 receptor antisense oligonucleotide complementary to any sequence of the human NPY Y2 receptor mRNA, said oligonucleotide having a length ranging from 7 to 40 nucleotides.
- 20 40. The method according to claim 39 wherein the antisense oligonucleotide contains 15 to 25 nucleotides, wherein the antisense oligonucleotide optionally contains one or more chemical modifications of the nucleotides.
- 25 41. The method according to claim 40 wherein one or more of the internucleotide linkages are modified, and/or wherein the oligonucleotide contains locked nucleic acid (LNA) modifications and/or wherein the oligonucleotide contains peptide nucleic acid (PNA) modifications.
- 30 42. The method according to claim 40 wherein one or more of the sugar units are modified, and/or one or more of the internucleotide linkages are modified, and/or one or more of the bases are modified and/or the oligonucleotide is end-protected by an inverted deoxyabasic sugar.

43. The method according to claim 42 wherein some or all of the sugar units of the antisense oligonucleotide are 2'-deoxyribose and/or wherein the internucleotide phosphodiester linkages are replaced by phosphorothioate linkages.
- 5 44. The method according to claim 39 wherein the antisense oligonucleotide is selected from a group consisting of
- 5'-CCTCTGCACCTATTGGACCC-3', (SEQ ID NO:2);
5'-GTTTGTGGCCCGTATTGTTCC-3', (SEQ ID NO:3);
5'-GGCCACTGTTCTTGACC-3', (SEQ ID NO:4);
10 5'-CTGCACCTATTGGACCCATT -3' (SEQ ID NO:7)
5'-CTCTGCACCTATTGGACCCA -3' (SEQ ID NO:8)
5'-GCCTCTGCACCTATTGGACC -3' (SEQ ID NO:9)
5'-CAGCCTCTGCACCTATTGGA -3' (SEQ ID NO:10)
5'-CGTATTGTTCCACCTTCATT -3' (SEQ ID NO:11)
15 5'-CCGTATTGTTCCACCTTCAT -3' (SEQ ID NO:12)
5'-CCCGTATTGTTCCACCTTCA -3' (SEQ ID NO:13)
5'-GCCCGTATTGTTCCACCTTC -3' (SEQ ID NO:14)
5'-GGCCCGTATTGTTCCACCTT -3' (SEQ ID NO:15)
5'-TTTCCACTCCCCCATTAAG -3' (SEQ ID NO:16)
20 5'-ATTTCACACTCCCCCATTA -3' (SEQ ID NO:17)
5'-CATTTCCACTCCCCCATTA -3' (SEQ ID NO:18)
5'-CCATTTCCACTCCCCCAT -3' (SEQ ID NO:19)
5'-CCCATTTCCACTCCCCCAT -3' (SEQ ID NO:20)
5'-CTCAATCAGCGAATACTCCC -3' (SEQ ID NO:21)
25 5'-GATCTCAATCAGCGAATACT -3' (SEQ ID NO:22)
5'-GCCACAATCTCAAAGTCCGG -3' (SEQ ID NO:23)
5'-GGCCACAATCTCAAAGTCCG -3' (SEQ ID NO:24)
5'-GCATTTGGTGGTTTTGC -3' (SEQ ID NO:25)
5'-CCAGCATTGGTGGTTTT -3' (SEQ ID NO:26)
30 5'-CCACACACACCAGCATTG -3' (SEQ ID NO:27)
5'-CCACCACCAACACACCAGC -3' (SEQ ID NO:28)
5'-CGCAAACACCACCACACAC -3' (SEQ ID NO:29)
5'-GCCAGCTGACCGCAAACACC -3' (SEQ ID NO:30)
5'-GCCTTCTGTAGTTGCTGTT -3' (SEQ ID NO:31)
35 5'-GGAAAGCCTTCTGTAGTTG -3' (SEQ ID NO:32)
5'-GGCCGAGAGGAAAGCCTTTC -3' (SEQ ID NO:33)
5'-CCACTGTTCTTCTGACCTC -3' (SEQ ID NO:34)
5'-GCCACTGTTCTTCTGACCT -3' (SEQ ID NO:35)
5'-GGGCCACTGTTCTTCTGAC -3' (SEQ ID NO:36)
40 5'-GGGGCCACTGTTCTTCTGA -3' (SEQ ID NO:37);

a combination of any of two or more of the aforementioned sequences or a combination of anyone of the aforementioned with another antisense

oligonucleotide such as human vascular endothelial growth factor antisense VEGF-AS, 5'-GCCTCGGCTTGTACATCTGC-3', (SEQ ID NO:41).

45. The method according to claim 44 wherein the sugar units of the antisense
5 oligonucleotides are 2'-deoxyribose and wherein the internucleotide linkages are
phosphorothioate linkages.

46. The method according to claim 34 wherein said agent is a selected from a group
consisting of

- 10 - a peptide,
- an antibody raised against the Y2 receptor or raised against an Y2-specific epitope
on the NPY peptide,
- an aptamer affecting the Y2 receptor or a Y2-specific NPY-conformation,
- a small interfering RNA molecule, or
- 15 - a ribozyme.

47. The method according to claim 34 wherein said agent is dipeptidylpeptidase IV
inhibitor, or an antisense oligonucleotide, an aptamer or antibody directed to
dipeptidylpeptidase IV.

20 48. The method according to claim 34 wherein said agent is a combination of agents
having ability to affect the action of NPY Y2 receptor.

FIG.1. Human Neuropeptide Y2 mRNA (shown as cDNA); Genbank Ref NM_000910; Orientation 5' → 3'. Three examples of antisense oligonucleotides (AS-1, AS-2 and AS-3) are inserted in bold. Also a known PCR primer is inserted

FIG.1, cont.

2761 gttaggacct ggattgagga ggtgtcagt tcgctgctcc ctgcttggct tataaaaaca
2821 ccactgaaca gaaatttc ttc caggagcca caggctctcc ttcatcgcat tttgatTTT
2881 ttgttcattc tctagacaaa atccatcagg gaatgtcga ggaaacgatt gccaactata
2941 cgaatggctt cgaggagata aactgaaatt tgctatataa ttaatatttt ggcagatgat
3001 agggaaactc ctcaacactc agtggccaa ttgttcttaa aaccaattgc acgtttgggt
3061 aaagtttctt caactctgaa tcaaagctg aaattctcag aattacagga aatgcaaacc
3121 atcatttaat ttctaatttc aagttacatc cgcttatgg agataactatt tagataacaa
3181 gaatacaact tgatacttt attgttatac cttttgaac atgtatgatt tctgttgta
3241 tttaccttt taaacagata aatattttt ttcatTTTA gagtagcgga atctaattctt
3301 aatctaattct tttaggaga tatttcagag aaattccaag cacaccagta tgaccatcct
3361 tatttcagaa atgacaatgc atagaggaaa agtaatatgt gcaaaggctc cgaagaggat
3421 ggttaagtAA agacttagt taccagtatc aggcttgcgt ttttgatgt aggtagctct
3481 actgcctcct cttaaaacca acaaaggaaa gagagactgg ctgcaaactt tttagaaggaa
3541 tggcttcgaa tagggttccct gggaggaatc cccggggaaat agacgctgct gctctgtga
3601 ttgtctccac tattctgttt tgctccatc cactaatcca gcctgggagg ctctgggcat
3661 tagcggaaagg cttcaccaca aggagacagg agcgagtatt ccataggcat gcgctccatg
3721 tggcacgagt ggcttgggtc aggatcaaag agtgaaggat tcggaagtca gctatctgga
3781 gagagagaga gattgtgtt tattctgtc ccatacgatTTT cctatccat ccataccta
3841 gcttttaacc tgagccagag ctcaatcac aggttccctgg ctatcgatc tgaatctgca
3901 ctactcaact tataaactgt ctgcagacac ctgttagggaa aattgtgtat catggggcggc
3961 aggatctgaa ctgcgtttac cttctgtttt ggagcacagg gaccggccag cttagaggagc
4021 accagcgcac tgcgcggccag ccctggcga gggtgccggag gattttctt cggtgcaatc
4081 ctgctggcgc ttttccgggg ttctgcgcgg atccagctcc ccatctctgc tcetacacac
4141 acaaaagaaa acaactctcg attggaaagg ttggaaattttt ctcagccccct acgaggcgcg
4201 gggattctcc agcccccggc ctccctccgc cagcctgagg tctccttcgc tcgcctgcct
4261 tgctagggac cgcagtcct cagccgcagc tgggtctgtc cgcggccct ttgcctcgc
4321 ctttcccg ggcggatttg gtgaagtccg cctcaagtcc aggaggctg tcttcgcgg
4381 gccagctc

3/6

Rat Neuropeptide Y2 receptor mRNA (shown as cDNA), coding region.

1 atgggccccat taggtgcaga ggcagatgag aatcaaactg tagaagtgaa agtggaaactc
61 tatgggtcgg ggcccaccac tccttagaggt gagttgcccc ctgatccaga gccggagctc
121 atagacagca ccaaactggc tgaggtgcag gtggcccta tactggccta ttgttccatc
181 atcttgctgg gcgttagttgg caactctcg gtaatccatg tggatgatcaa attcaagagc
241 atgcgcacag taaccaacctt ttttattgcc aacctggctg tggcggatct tttggtaac
301 accctgtgcc tgccattcac tcttacatat accttgatgg gggagtggaa aatgggtcca
361 gttttgtgcc atttggtgcc ctatgcccag ggtctggcag tacaagtgtc cacaataact
421 ttgacagtca ttgttttggc ccgacatctg tgcatttgtct accacctggc gagcaagatc
481 tccaaggaaa tcagcttcctt gattattggc ctggcgtggg gtgtcagcgc tctgctggca
541 agtcccccttg ccacatcccg ggagtactca ctgattgaga ttattcctga cttttagatt
601 gtagccctgtatcgagaaatg gccccggggag gagaagagtg tgtacggtagt agtctacagc
661 ctttccaccc tgcataatccctt ctacgttttgc cctctggca tcatatcttt ctcctacacc
721 cggatctggatgtaagctaaa gaaccacgtt agtctggag ctgcaagtga ccattaccat
781 cagcgaaggc acaaaacgac caaaatgttc gtgtcgtgg tagtgggtgt tgcaagttagc
841 tggctggccc tccatgcctt ccaacttgct gtggacatcg acagccatgt cctggacctg
901 aaggagataca aactcatctt caccgtgtt cacattatttgc cgtatgtgtc cacccttcgccc
961 aacccccc tctatggctg gatgaacagc aactacagaa aagtttcctt ctcagccttc
1021 cgctgtgagc agaggttggc tgccattcac tcggaggtgt ccatgacctt caaggctaaa
1081 aagaacctgg aagtcaaaaaa gaacaatggc ctcactgact cttttcaga ggccaccaac
1141 gtgttaag

FIG. 2

4/6






FIG. 3


BEST AVAILABLE COPY



4a



4b



4c




FIG. 4




FIG. 5

BEST AVAILABLE COPY

sequence listing.txt
SEQUENCE LISTING

<110> Hormos Medical Corporation

<120> Method for Prevention and Treatment of Diseases or Disorders Related to Excessive Formation of Vascular Tissue or Blood Vessels

<130> NPY-retino/HP1287

<150> US 60/_____

<151> 2002-06-27

<160> 42

<170> PatentIn version 3.0

<210> 1

<211> 4390

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1252)..(1254)

<223> start codon

<220>

<221> misc_feature

<222> (2395)..(2397)

<223> stop codon

<400> 1
tatcctatcc ctatccttagc ttttaacctg agccagagct cactacacag gttcctggct 60
atcgagtctg aatctgcact actcaactta taaactgtct gcagacacct gttaggaaaa 120
ttgctgatca tgggcggcag gatctgaact cgctttacct tcttgtttgg agcacaggga 180

sequence listing.txt

ccgcccagct	agaggagcac	cagcgactg	cgccccagcc	ctggcgagg	gtgcggagga	240
tttgttctcg	gtcaatcct	gctggcgctt	ttccggggtt	ctgcgcggat	ccagctcccc	300
atctctgctc	ctacacacac	aaaagaaaaac	aactctcgat	tgaaagttgt	ggaattttct	360
cagcccc tac	gaggcgccgg	gattctccag	ccccggccct	cctcccgcca	gcctgaggtc	420
tccttcgctc	gcctgccttg	ctagggaccg	cagtccctca	gccgcagctg	ggtctgtccg	480
ccccgcctt	gccctcgccct	tttcccgggg	cggatttgg	gaagtccggcc	tcaagtccag	540
gaggctgtc	ttcgccggc	cagctctcg	ggaactgggg	ggttagagagc	aaagggagag	600
attcgtggaa	gggaaggggag	gtaggggtgg	cgcaaacgcc	cagagtatca	aacttggggg	660
tggcacagta	ggtgacagca	gcagctgcag	gtggtggtcg	gggacccgcg	agggggcgcc	720
cctctggta	gggtctggct	gagcgggctt	gcaagcccg	gaggccgctg	agagaccctg	780
gacactgttc	ctgctccctc	gccaccaaaa	cttctctcc	agtccctcc	cctgcaggac	840
catcgcccg	agcctctgca	cctgtttct	tgtgttaag	ggtgggttt	gccccctcc	900
ccacgctccc	atctctgatc	ctcccacctt	cacccgccc	ccccgcgagt	gagtgcggtg	960
cccaggcg	cttggcctga	gaggtcggca	gcagacccgg	cagcgccaaac	cgcccagccg	1020
ctctgactgc	tccggctgcc	cgccccgcg	gcgcgggctg	tcctggaccc	taggagggga	1080
cggAACCGGA	cttgccttt	ggcaccttcc	agggccctct	ccaggtcggc	tggctaata	1140
tcggacagac	ggactgcaca	catcttgttt	ccgcgtctcc	gcaaaaacgc	gaggtccagg	1200
tcagttgtag	actcttgc	tgtgtcagg	ccaagtggac	ctgtactgaa	aatgggtcca	1260
ataggtgcag	aggctgatga	gaaccagaca	gtgaaagaaa	tgaaggtgga	acaatacggg	1320
ccacaaacaa	ctcctagagg	tgaactggtc	cctgaccctg	agccagagct	tatagatagt	1380
accaagctga	ttgaggtaca	agttgttctc	atattggct	actgctccat	catcttgctt	1440
gggtaattt	gcaactccctt	ggtgatccat	gtggatcatca	aattcaagag	catgcgcaca	1500
gtaaccaact	ttttcattgc	caatctggct	gtggcagatc	ttttggtaaa	cactctgtgt	1560
ctaccgttca	cttttaccta	taccttaatg	ggggagtgg	aaatgggtcc	tgtcctgtgc	1620
cacctggtgc	cctatgccc	gggcctggca	gtacaagtat	ccacaatcac	cttgacagta	1680
attgcccctgg	accggcacag	gtgcacatgc	taccacctag	agagcaagat	ctccaagcga	1740
atcagcttcc	tgattattgg	cttggcctgg	ggcatcagt	ccctgctggc	aagtccctg	1800
gccatcttcc	gggagtattt	gctgattgag	atcatcccg	actttgagat	tgtggcctgt	1860
actgaaaagt	ggcctggcga	ggagaagagc	atctatggca	ctgtctatag	tctttcttcc	1920
ttgttgc	tgtatgtttt	gcctctggc	attatatcat	tttcctacac	tcgcatttgg	1980
agtaaattga	agaaccatgt	cagtccctgg	gctgcaaatg	accactacca	tcagcgaagg	2040
caaaaaacca	ccaaaatgct	ggtgtgtgt	gtgggtgtgt	ttgcggtcag	ctggctgcct	2100
ctccatgcct	tccagcttgc	cgttgcacatt	gacagccagg	tcctggacct	gaaggagat	2160
aaactcatct	tcacagtgtt	ccacatcatc	gccatgtgct	ccactttgc	caatccctt	2220

sequencelisting.txt

ctctatggct	ggatgaacag	caactacaga	aaggcttcc	tctcggcctt	ccgctgttag	2280
cagcggttgg	atgccattca	ctctgaggtg	tccgtacat	tcaaggctaa	aaagaacctg	2340
gaggtcagaa	agaacagtgg	ccccaatgac	tcttcacag	aggctaccaa	tgtctaagga	2400
agctgtggtg	tgaaaatgta	tggatgaatt	ctgaccagag	ctatgaatct	ggttgatggc	2460
ggctcacaag	tgaaaactga	tttcccattt	taaagaagaa	gtggatctaa	atggaagcat	2520
ctgctgttta	attcctggaa	aactggctgg	gcagagcctg	tgtaaaata	ctgaaattca	2580
aagataaggc	aacaaaatgg	tttacttaac	agttgggtgg	gttagtagtt	gcattatgag	2640
taaaaagcaga	gagaagtact	tttgattatt	ttcctggagt	gaagaaaaact	tgaacaagaa	2700
attggtatta	tcaaagcatt	gctgagagac	ggtggggaaa	taagttgact	ttcaaattcac	2760
gttaggacct	ggattgagga	ggtgtgcagt	tcgctgtcc	ctgctggct	tatgaaaaca	2820
ccactgaaca	gaaatttctc	cagggagcca	caggctctcc	ttcatcgcat	tttgatttt	2880
ttgttcattc	tctagacaaa	atccatcagg	aatgctgca	ggaaacgatt	gccactata	2940
cgaatggctt	cgaggagata	aactgaaatt	tgctatataa	ttaatatttt	ggcagatgat	3000
aggggaactc	ctcaacactc	agtggccaa	ttgttctaa	aaccaattgc	acgtttggtg	3060
aaagtttctt	caactctgaa	tcaaaagctg	aaattctcag	aattacagga	aatgcaaacc	3120
atcatttaat	ttctaatttc	aagttacatc	cgctttatgg	agatactatt	tagataacaa	3180
gaatacaact	tgatactttt	attgttatac	cttttgaac	atgtatgatt	tctgttgtta	3240
tttacctttt	taaacagata	aatatttttt	tttcattttt	gagtagcgg	atctaattctt	3300
aatctaattct	tttaggagta	tatccagag	aaattccaag	cacaccagta	tgaccatcct	3360
tatccagaa	atgacaatgc	atagaggaaa	agtaatatgt	gcaaagcctc	cgaaggagat	3420
ggttaagtaa	agacttaggt	taccagtatc	aggcttcgt	ttttgtatgt	aggtagctct	3480
actgcctcct	cttaaaacca	acaaaggaaa	gagagactgg	ctgcaaactt	ttagaaggaa	3540
tggcttcgaa	tagggttcct	gggaggaatc	ccgagggaaat	agacgctgct	gctctgctga	3600
ttgtctccac	tatccctgttt	tgctcctacc	cactaatcca	gcctgggagg	ctctgggcat	3660
tagcggagg	tttcaccaca	aggagacagg	agcgagtatt	ccataggcat	gcgcctctag	3720
tggcacgagt	ggcttgggtc	aggatcaaag	agtgaaggat	tcggaagtca	gctatctgga	3780
gagagagaga	gattgtgttt	tattcgtgtc	ccatagcttt	cctatcctat	ccctatccct	3840
gcttttaacc	tgagccagag	ctcaactacac	agttcctgg	ctatcgagtc	tgaatctgca	3900
ctactcaact	tataaactgt	ctgcagacac	ctgttaggga	aattgctgat	catggcggc	3960
aggatctgaa	ctcgctttac	tttctgtttt	ggagcacagg	gaccgcccag	ctagaggagc	4020
accagcgcac	tgcgc(cc)ag	ccctgggcga	gggtgcggag	gatttgttct	cggtgcaatc	4080
ctgctggcgc	ttttccgggg	ttctgcgcgg	atccagctcc	ccatctctgc	tcctacacac	4140
acaaaagaaa	acaactctcg	attggaagtt	gtggaatttt	ctcagcccc	acgaggcgcg	4200
gggattctcc	agccccggcc	ctcccccgc	cagcctgagg	tctccttcgc	tcgcctgcct	4260

sequence listing.txt
tgcttagggac cgca^gtcc^c cagccgc^ag^c tgggtctg^t c^gccccgc^c ttgc^cc^tcg^c 4320
ctttccc^g ggcggat^ttg gtgaagt^cgg cctcaag^tcc aggagg^tc^tg tcttcg^ccg^g 4380
gccag^ct^ctc^c 4390

<210> 2
<211> 20
<212> DNA
<213> Homo sapiens

<400> 2
cctctgcacc tattggaccc 20

<210> 3
<211> 21
<212> DNA
<213> Homo sapiens

<400> 3
gtttgtggcc cgtattgttc c 21

<210> 4
<211> 20
<212> DNA
<213> Homo sapiens

<400> 4
ggccactgtt ctttctgacc 20

<210> 5
<211> 19
<212> DNA
<213> Homo sapiens

<400> 5
gttgacatt^g acagccagg 19

<210> 6
<211> 1147
<212> DNA

sequencelisting.txt

<213> Rattus sp.

<400> 6	
atgggcccattaggtgcaga ggcagatgag aatcaaactg tagaaagtgaa agtggaaactc	60
tatgggtcgggccaccac tccttagaggt gagttcccc ctgatccaga gccggagctc	120
atagacagca ccaaactgg ttaggtgcag gtggcccta tactggcta ttgttccatc	180
atcttgctgg gcgtagttgg caactctctg gtaatccatg tggtgatcaa attcaagagc	240
atgcgcacag taaccaactt ttttattgcc aacctggctg tggcgatct tttggtaac	300
accctgtgcc tgccattcac tcttacctat accttgcatttgg gggagtggaa aatgggtcca	360
gttttgtgcc atttggtgcc ctatgcccag ggtctggcag tacaagtgtc cacaataact	420
ttgacagtca ttgctttggc ccgacatcgt tgcattgtct accacctggc gagcaagatc	480
tccaagcaaa tcagcttcct gattattggc ctggcgtggg gtgtcagcgc tctgctggca	540
agtcccccttgc catcttccggagactca ctgattgaga ttattcctga ctttgagatt	600
gtagcctgta ctgagaaaatg gcccggggag gagaagagtg tgtacggtagt acgtctacagc	660
ctttccaccc tgctaattcct ctacgttttgc cctctggca tcataatctt ctcctacacc	720
cggatctggc gtaagctaaa gaaccacgtt agtcctggag ctgcaagtga ccattaccat	780
cagcgaaggc aaaaaacgac caaaatgctc gtgtcgtgg tagtgggttt tgcaagtgc	840
tggctgcccc tccatgcctt ccaacttgct gtggacatcg acagccatgt cctggacctg	900
aaggagtaca aactcatctt caccgtgttc cacattatttgcgtgtc caccctcgcc	960
aacccccc tctatggctg gatgaacagc aactacagaa aagcttcct ctcagccttc	1020
cgctgtgagc agagggttggc tgccattcac tcggagggtgtt ccatgacctt caaggctaaa	1080
aagaacctgg aagtcaaaaaa gaacaatggc ctcactgact cttttcaga ggccaccaac	1140
gtgttaag	1147

<210> 7

<211> 20

<212> DNA

<213> Homo sapiens

<400> 7	
ctgcacccat tggaccatt	20

<210> 8

<211> 20

<212> DNA

<213> Homo sapiens

sequencelisting.txt

<400> 8
ctctgcacct attggaccca 20

<210> 9

<211> 20

<212> DNA

<213> Homo sapiens

<400> 9
gcctctgcac ctattggacc 20

<210> 10

<211> 20

<212> DNA

<213> Homo sapiens

<400> 10
cagcctctgc acctattgga 20

<210> 11

<211> 20

<212> DNA

<213> Homo sapiens

<400> 11
cgtattgttc cactttcatt 20

<210> 12

<211> 20

<212> DNA

<213> Homo sapiens

<400> 12
ccgtattgtt ccacccat 20

<210> 13

<211> 20

<212> DNA

sequencelisting.txt

<213> Homo sapiens

<400> 13
cccggtattgt tccaccttca

20

<210> 14

<211> 20

<212> DNA

<213> Homo sapiens

<400> 14
gccccgtatttg ttccaccttc

20

<210> 15

<211> 20

<212> DNA

<213> Homo sapiens

<400> 15
ggcccggtattt gttccacctt

20

<210> 16

<211> 20

<212> DNA

<213> Homo sapiens

<400> 16
ttttccactc ccccatthaag

20

<210> 17

<211> 20

<212> DNA

<213> Homo sapiens

<400> 17
attttccact ccccccattaa

20

<210> 18

<211> 20

sequence listing.txt

<212> DNA

<213> Homo sapiens

<400> 18

cattttccac tcccccatta

20

<210> 19

<211> 20

<212> DNA

<213> Homo sapiens

<400> 19

ccatTTTCCA CTCCCCCATT

20

<210> 20

<211> 20

<212> DNA

<213> Homo sapiens

<400> 20

cccattttcc actcccccat

20

<210> 21

<211> 20

<212> DNA

<213> Homo sapiens

<400> 21

ctcaatcagc gaataactccc

20

<210> 22

<211> 20

<212> DNA

<213> Homo sapiens

<400> 22

gatctcaatc agcgaatact

20

<210> 23

sequence listing.txt

<211> 20

<212> DNA

<213> Homo sapiens

<400> 23

gccacacaatct caaaagtccgg

20

<210> 24

<211> 20

<212> DNA

<213> Homo sapiens

<400> 24

ggccacacaatc tcaaagtccg

20

<210> 25

<211> 20

<212> DNA

<213> Homo sapiens

<400> 25

gcatttttgtt ggttttttgc

20

<210> 26

<211> 20

<212> DNA

<213> Homo sapiens

<400> 26

ccagcattttt ggtgggtttt

20

<210> 27

<211> 20

<212> DNA

<213> Homo sapiens

<400> 27

ccacacacac cagcattttg

20

sequencelisting.txt

<210> 28

<211> 20

<212> DNA

<213> Homo sapiens

<400> 28

ccaccaccac acacaccaggc

20

<210> 29

<211> 20

<212> DNA

<213> Homo sapiens

<400> 29

cgcggaaacacc accaccacac

20

<210> 30

<211> 20

<212> DNA

<213> Homo sapiens

<400> 30

gccagctgac cgcaaacacc

20

<210> 31

<211> 20

<212> DNA

<213> Homo sapiens

<400> 31

gcctttctgt agttgctgtt

20

<210> 32

<211> 20

<212> DNA

<213> Homo sapiens

<400> 32

sequencelisting.txt

ggaaaggcctt tctgttagttg

20

<210> 33

<211> 20

<212> DNA

<213> Homo sapiens

<400> 33

ggccgagagg aaagcctttc

20

<210> 34

<211> 20

<212> DNA

<213> Homo sapiens

<400> 34

ccactgttct ttctgacctc

20

<210> 35

<211> 20

<212> DNA

<213> Homo sapiens

<400> 35

gccactgttc tttctgacct

20

<210> 36

<211> 20

<212> DNA

<213> Homo sapiens

<400> 36

ggccactgt tctttctgac

20

<210> 37

<211> 20

<212> DNA

<213> Homo sapiens

sequence listing.txt

<400> 37
ggggccactg ttctttctga 20

<210> 38

<211> 20

<212> DNA

<213> Rattus sp.

<400> 38
cctctgcacc taatgggcc 20

<210> 39

<211> 20

<212> DNA

<213> Rattus sp.

<400> 39
ccatggtaat ccggcgctcc 20

<210> 40

<211> 20

<212> DNA

<213> Homo sapiens

<400> 40
cccaggttat ccacgtctcc 20

<210> 41

<211> 21

<212> DNA

<213> Homo sapiens

<400> 41
gcctcggctt gtcacatctg c 21

<210> 42

<211> 3747

<212> DNA

<213> Homo sapiens

sequencelisting.txt

<220>
<221> misc_feature
<222> (496)..(498)
<223> start codon

<220>
<221> misc_feature
<222> (1639)..(1641)
<223> stop codon

<400> 42
gaattcggcc gctgagagac cctggacact gttcctgctc cctcgccacc aaaacttctc 60
ctccagtccc ctccccctgca ggaccatcgc ccgcagccctc tgcacctgtt ttcttggtt 120
taagggtggg gtttgcffff ctcggccacgc tcccatctct gatccctccca ccttcacccg 180
cccaccccgcc gagtgagtgc ggtgcccagg cgcgcttggc ctgagaggtc ggcagcagac 240
ccggcagcgc caaccggcca gccgctctga ctgctccggc tgcccggcc cgccggcgcgg 300
gctgtcctgg acccttaggag gggacggaac cggacttgcc tttgggcacc ttccagggcc 360
ctctccaggt cggtggcta atcatcggac agacggactg cacacatctt gtttccgcgt 420
ctccgaaaa acgcgaggc caggtcagtt gtagactctt gtgctgggt 480
ggacctgtac tgaaaatggg tccaataggt gcagaggctg atgagaacca gacagtggaa 540
gaaatgaagg tggacaata cgggcccacaa acaactccta gaggtgaact ggtccctgac 600
cctgagccag agcttataga tagtaccaag ctgattgagg tacaagttgt tctcatattg 660
gcctactgct ccatcatctt gcttgggtta attggcaact cttgggtat ccatgtggtg 720
atcaaattca agagcatgcg cacagtaacc aacttttca ttgccaatct ggctgtggca 780
gatctttgg tgaacactct gtgtctaccg ttcaacttta cctataccctt aatgggggag 840
tggaaaatgg gtcctgtcct gtgccacctg gtgcctatg cccagggcct ggcagtacaa 900
gtatccacaa tcaccttgac agtaattgcc ctggaccggc acaggtgcac cgtctaccac 960
ctagagagca agatctccaa gcbaatcgcg ttcctgatta ttggcttggc ctggggcatc 1020
agtgcctgc tggcaagtcc cctggccatc ttccggaggt attcgctgat tgagatcatt 1080
ccggactttg agattgtggc ctgtactgaa aagtggctg gcgaggagaa gagcatctat 1140
ggcactgtct atagtcttc ttccctgtt 1140
tgcattttccat acactcgcacat ttggagtaaa ttgaagaacc atgtcagtcc tggagctgca 1260
aatgaccact accatcagcg aaggcaaaaa accaccaaaa tgctgggttg tgtgggttg 1320

sequencelisting.txt

gtgtttgcgg tcagctggct gcctctccat gccttccagc ttgccgttga cattgacagc	1380
caggtcctgg acctgaagga gtacaaactc atcttcacag tggccacat tatcgccatg	1440
tgctccactt ttgccaatcc ccttctctat ggctggatga acagcaacta cagaaaggct	1500
ttcctctcgg cttccgctg tgagcagcgg ttggatgcca ttcaactctga ggtgtccgtg	1560
acattcaagg ctaaaaagaa cctggaggc agaaagaaca gtggccccaa tgactcttc	1620
acagaggcta ccaatgtcta aggaagctgt ggtgtaaaaa tgtatggatg aattctgacc	1680
agagctatga atctgggttga tggcggctca caagtaaaaa ctgatttccc attttaaaga	1740
agaagtggat ctaaatggaa gcatctgctg ttaattcct ggaaaactgg ctgggcagag	1800
cctgtgtgaa aatactggaa ttcaaagata aggcaacaaa atggtttact taacagttgg	1860
ttggtagta ggttgcatta tgagtaaaag cagagagaag tacttttgc tattttcctg	1920
gagtgaagaa aacttgaaca agaaattggt attatcaaag cattgctgag agacggtggg	1980
aaaataagtt gactttcaaa tcacgtttagg acctggattt agggaggtgtg cagttcgctg	2040
ctccctgctt ggcttatgaa aacaccactg aacagaaatt tctccaggga gccacaggct	2100
ctccttcatc gcattttgat tttttgttc attctctaga caaaatccat caggaaatgc	2160
tgcaggaaac gattgccaac tatacgaatg gtttcgagga gataaaactga aatttgctat	2220
ataattaata ttttggcaga tgatagggga actcctcaac actcagtggg ccaatttttc	2280
ttaaaaccaa ttgcacgtt ggtgaaagtt tttcaactc tgaatcaaaa gctgaaattc	2340
tcagaattac aggaaatgc aaccatcatt taatttctaa ttcaagttt catccgctt	2400
atggagatac tatttagata acaagaatac aacttgatac ttttattgtt atacctttt	2460
gaacatgtat gatttctgtt gttattccta ttggagctaa gtttgtctac actaaaattt	2520
aaatcagact agagaataat ttttggca tggtaaca tttcacagta tttacaagct	2580
attttgcac aggtacatag ctctcatgtt tttaaagaac actgcagtgt tatttcttt	2640
gaaattcattc ctccacggac ccattcatac taaataaaac aatgtatattt cattaaaatg	2700
gacctatctg taagaggtac taaaacact ggattcattt catttgcaa atgttgatt	2760
tcaaccaggat ttcacataag ttatttgc tttttcaaa ataatttagct atattttat	2820
ataatatgaa tatatacata aaaattgttt ctataaattt tagaacatag atgctacagt	2880
attttttattt taatttatattt atgaataaaaa ttgttatttc aatagtaccc aaccaaagat	2940
gcttaaaaac cttctatgtt cataaaaaat aacaactgag atgtttttt agtcatacgt	3000
cttttagatgc tattaaagtt tcatttagtca tattttgtt aatatgacag aatttgcgaa	3060
tatattttta aagcaaaaaa cttcaacatg catatgatat atagttacaa cattatattt	3120
atgaactgga gagctttact ttgtggatattt aataaaattt catattatag cttctattaa	3180
attccttcca tggatagatata aaaggactgg ttttaagtg cactgcactt ctggaaactt	3240
gaaaaagaat gaaaacaata tggtagatta ggtgtaaagac tttaagaagc gaacaaaaag	3300
taatgtatata ctgtatata taatcaaattt attcattttt ctgttagact aggcaaaattt	3360

sequence listing.txt

ttcaaaaata accttttgt cttaagta gcagtcactt tgcttaagat gctaata aactgtggtt aaagatttac cccctctt ggtgaattat tacactgtaa gaaatgtata	3420
tgctactgtg ttacatgttg tattagtaaa ttattagaat ccaattaatg attcaattaa	3480
catatatctt atccaattca ttatgtcaat tcattaataa aatacccttt atgttagaggc	3540
tttatgttgc aattaaaaag ttggggaaat gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	3600
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	3660
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	3720
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	3747

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 03/00487

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 48/00, A61K 38/00, A61K 39/395, A61K 31/00, A61P 9/10, C12N 15/11
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM. ABS DATA, MEDLINE, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Circ Res, Volume 83, 1998, Zofia Zukowska-Grojec et al: "Neuropeptide Y. A Novel Angiogenic Factor From the Sympathetic Nerves and Endothelium", page 187 - page 195, the whole document --	1-15, 29-31, 34-48
X	US 5989834 A (CHRISTOPHE GERALD ET AL), 23 November 1999 (23.11.99), column 15, lines 55-62; column 17, line 1 - column 18, line 40; column 19, lines 44-56; column 46, table 7; column 41, lines 32-42; column 35, lines 31-37	16-28, 32-33
Y	--	1-4, 6-15, 29-31, 34-37, 39-48

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search	Date of mailing of the international search report
2 October 2003	06-10-2003
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. + 46 8 666 02 86	Authorized officer Ida Christensen/EÖ Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 03/00487

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Molecular Brain Research, Volume 46, 1997, Eric L. Gustafson et al: Distribution of the neuropeptide Y Y2 receptor mRNA in rat central nervous system", page 223 - page 235, abstract; page 226, column 1, paragraph 2 --	16-28,32
Y	The Journal of Biological Chemistry, Volume 277, no. 13, 2002, Daniela Prosko et al: "A Y2 Receptor Mimetic Aptamer Directed against Neuropeptide Y", page 11416 - page 11422, abstract; page 11421, column 2, last paragraph --	13,46
Y	Peptides, Volume 22, 2001, Giulio Ghersi et al: "Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding", page 453 - page 458, whole document --	5,14,38,47
A	Regulatory Peptides, Volume 67, 1996, D. Grandt et al: "Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors", page 33 - page 37, page 36, column 2 --	14,47
A	DIABETES, Volume 51, April 2002, J.A. Pospisilik et al: "Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and Beta-Cell Glucose Responsiveness in VDF (fa/fa) Zucker Rats", page 943 - page 950 --	14,47
A	Biochemical Pharmacology, Vol. 54, 1997, Ingrid De Meester et al: "In Vivo Inhibition of Dipeptidyl Peptidase IV Activity by Pro-Pro-diphenyl-phosphonate (Prodipine)", page 173 - page 179, abstract; page 178, column 1, last paragraph --	14,47

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 03/00487

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 0204518 A2 (BAYER CORPORATION), 17 January 2002 (17.01.02), page 4, lines 16-20; page 30, lines 19-27; page 32, lines 6-28; page 51, lines 19-20; page 52, lines 14-15; page 69, lines 20-21 --	1-48
A	WO 9717440 A1 (GARVAN INSTITUTE OF MEDICAL RESEARCH), 15 May 1997 (15.05.97), page 13, lines 8-14; page 7, lines 25-26; page 5, lines 11-16 --	1-48
A	Exp Clin Endocrinol Diabetes, Volume 108, 2000, L. Niskanen et al: "Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with retinopathy in Type 2 diabetes", page 235 - page 236, the discussion --	1-48
A	Neuroscience, Volume 98, no. 4, 2000, R.T.F. Cheung et al: "Neuropeptide Y-Y1 receptor antisense oligodeoxynucleotide increases the infarct volume after middle cerebral artery occlusion in rats", page 771 - page 777, abstract --	1-48
A	Regulatory Peptides, Volume 75-76, 1998, Zofia Zukowska-Grojec et al: "Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors", page 231 - page 238 -----	1-48

INTERNATIONAL SEARCH REPORT

International application No.
PCT/FI03/00487

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: **1-5, 13, 15, 34, 38, 46, 48 (partially)**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see next sheet

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/FI03/00487

Present claims 1-5, 13, 15, 34-38, 46 and 48 relate to the use of an extremely large number of possible compounds, acting as "agents affecting the NPY Y2 receptor". Support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the agents claimed. Further, in claims 1 and 34, the expression "disease or disorder related to excessive formation of vascular tissue or blood vessels" covers an extremely large number of possible disorders. Support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the disorders claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts related to the antisense oligonucleotides having the sequences of SEQ ID NO 2, 3, 4 and 38. Further, a search for the general aspects of the invention, covering the agents and the disorders mentioned in the description, has been carried out as far as possible. The antisense oligonucleotides having the sequences of SEQ ID NO 7-37 have also been searched.

The applicant's attention is drawn to the fact that claims or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.:

06/09/03

PCT/FI 03/00487

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5989834 A	23/11/99	AU	697271 B	01/10/98
		AU	1743295 A	21/08/95
		DE	802972 T	19/02/98
		EP	0802972 A	29/10/97
		GR	97300046 T	31/12/97
		JP	9509314 T	22/09/97
		CA	2159217 A	10/08/95
		ES	2107398 T	01/12/97
		US	5545549 A	13/08/96
		US	6420532 B	16/07/02
		US	2003162944 A	28/08/03
		WO	9521245 A	10/08/95
<hr/>		AU	7183801 A	21/01/02
<hr/>		US	2002048791 A	25/04/02
<hr/>		AU	7485996 A	29/05/97
<hr/>		AU	PN646795 D	00/00/00
<hr/>		EP	0862627 A	09/09/98
<hr/>		JP	2000500648 T	25/01/00
<hr/>		US	6528303 B	04/03/03